Clinical Factors and Adverse Kidney Outcomes in Children With Antineutrophil Cytoplasmic Antibody–Associated Glomerulonephritis

Marlais, Matko; Wlodkowski, Tanja; Printza, Nikoleta; Kronsteiner, Dorothea; Krisam, Regina; Sauer, Lukas D; Aksenova, Marina; Ashoor, Isa; Awan, Atif; Bacchetta, Justine; Balasubramanian, Ramnath; Basu, Biswanath; Békássy, Zivile; Boyer, Olivia; Chan, Eugene Yu-hin; Csaicsich, Dagmar; Decramer, Stéphane; Dorresteijn, Eiske M.; Drożyńska-Duklas, Magdalena; Eid, Loai Akram; Espinosa, Laura; Ferraris, Verónica; Flögelová, Hana; Forero-Delgadillo, Jessica María; Gianviti, Alessandra; Gracchi, Valentina; González, María López; Hansen, Matthias; Hattori, Motoshi; Xu, Hong; Hooman, Nakysa; Иванов, Д Д; Kang, Hee Gyung; Karava, Vasiliki; Kazyra, I. A.; Lungu, Adrian; Marks, Stephen; Maxted, Andrew P.; Moczulska, Anna; Müller, Rebekka; Настаушева, Т. Л.; Parolin, Mattia; Pecoraro, Carmine; Principi, Iliana; Sanchez-Kazi, Cheryl; Saygılı, Seha; Schild, Raphael; Shenoy, Mohan; Sinha, Rajiv; Spizzirri, Ana P.; Stack, Maria; Szczepańska, Maria; Цыгин, А. Н.; Tzeng, Julia; Urbonas, Vaidotas; Zapata, Carlos Mario; Zieg, Jakub; Schaefer, Franz; Vivarelli, Marina; Tullus, Kjell

doi:10.1053/j.ajkd.2022.05.013

Cited by 10 publications

(7 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 26 , 32 The use of rituximab in LN remains controversial as compared with other pediatric glomerular conditions. 33 , 34 , 35 , 36 Newly approved treatments for LN such as belimumab and voclosporin may offer new hope to managing cLN. Unfortunately, none of these recent clinical trials have involved children with severe LN, and this calls for initiatives to involve pediatric populations in future drug development programs.…”

Section: Discussionmentioning

confidence: 99%

Long-Term Outcomes of Children and Adolescents With Biopsy-Proven Childhood-Onset Lupus Nephritis

Chan¹,

Yap²,

Wong³

et al. 2023

Kidney International Reports

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Long-Term Outcomes of Children and Adolescents With Biopsy-Proven Childhood-Onset Lupus Nephritis

Chan¹,

Yap²,

Wong³

et al. 2023

Kidney International Reports

Self Cite

View full text Add to dashboard Cite

“…Rituximab has emerged as an important therapeutic option in several pediatric immunemediated glomerular diseases, such as idiopathic nephrotic syndrome and ANCA-associated vasculitis glomerulonephritis. 2,22,23 Our data showed that rituximab exposure up to 1 year prior to vaccination resulted in poor immunogenicity. Furthermore, patients with glomerular disease are at risk of relapse and often require multiple courses of rituximab to maintain disease remission.…”

Section: Discussionmentioning

confidence: 75%

Humoral and Cellular Immunogenicity and Safety of 3 Doses of CoronaVac and BNT162b2 in Young Children and Adolescents with Kidney Diseases

Leung

Chan

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. CoronaVac and BNT162b2 in pediatric kidney patients 2 SIGNIFICANCE STATEMENT Little is known about the effectiveness of COVID-19 vaccines in children and adolescents with kidney diseases. This paper describes the antibody and T cell responses of 3 doses of CoronaVac or BNT162b2, the top 2 COVID-19 vaccines distributed worldwide, by an accelerated regimen in patients with kidney diseases aged 1-18 years. Antibody and T cell responses were significantly elicited by either vaccine. Neutralization was reduced against Omicron while T cell response was preserved, which likely confer protection against severe COVID-19. Rate of severe adverse reactions was low in the study. Results confirm that accelerated 3-dose primary series with CoronaVac and BNT162b2 is safe and immunogenic in young children and adolescents with kidney diseases.

show abstract

“…AAV have the potential to be life threatening and often are associated with marked morbidity and mortality. Unfortunately, most available evidence stems from studies in adults as there are only a few small studies done in the pediatric population [4,5 ▪ ,29 ▪▪ ,30 ▪▪ ]. Similarly to LN, the treatment approach is rapidly evolving as the pharmacologic options are growing, so new studies are constantly changing the way we approach the disease.…”

Section: Anti-neutrophil Cytoplasmic Antibody Associated Vasculitidesmentioning

confidence: 99%

“…Overall, 40% of patients required KRT at the last follow up at a median of 26 months post diagnosis. Predictors of KRT requirement were need of plasmapheresis at presentation and high serum creatinine levels at 3 months initiation of treatment or presentation [30 ▪▪ ]. A retrospective study of pediatric AAV reported that older age at diagnosis, high serum creatinine at diagnosis and sclerotic changes on kidney biopsy were all associated with poor kidney outcome and a high risk of developing ESKD.…”

Section: Anti-neutrophil Cytoplasmic Antibody Associated Vasculitidesmentioning

confidence: 99%

Renal disease in pediatric rheumatology

Cody,

Brunner

2024

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of review This review will provide updates in the outcomes in the common rheumatologic diseases with kidney involvement. Covered are also advances in therapeutics for the use of pediatric rheumatologic diseases with kidney involvement, as well as the potential kidney complications from other rheumatologic diseases and their medications. Recent findings Two of the more common rheumatologic diseases with kidney involvement, lupus and vasculitis, continue to show inadequate response to initial therapy of renal disease and practice continues to be driven by results of adult studies. Summary There is a continued need for pediatric specific studies in rheumatologic diseases with kidney involvement as outcomes continue to be inadequate. Despite recently approved treatments for adults with rheumatic diseases and kidney involvement, therapeutic options in pediatrics remain limited, contributing to the overall morbidity and mortality.

show abstract

Clinical Factors and Adverse Kidney Outcomes in Children With Antineutrophil Cytoplasmic Antibody–Associated Glomerulonephritis

Cited by 10 publications

References 5 publications

Long-Term Outcomes of Children and Adolescents With Biopsy-Proven Childhood-Onset Lupus Nephritis

Long-Term Outcomes of Children and Adolescents With Biopsy-Proven Childhood-Onset Lupus Nephritis

Humoral and Cellular Immunogenicity and Safety of 3 Doses of CoronaVac and BNT162b2 in Young Children and Adolescents with Kidney Diseases

Renal disease in pediatric rheumatology

Contact Info

Product

Resources

About